title: Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapine.
abstract: The objective of this study was to evaluate the applicability of saliva as an alternative body fluid for therapeutic drug monitoring of nevirapine. The pharmacokinetics of nevirapine in plasma and saliva during a dosing interval was assessed in HIV-1-infected patients taking nevirapine (200 mg twice daily) to explore the relation between the concentration of nevirapine in plasma and saliva. To validate the anticipated relationship prospectively, single, paired plasma and saliva samples were obtained from nevirapine-treated HIV-1-infected outpatients. The plasma nevirapine concentration was strongly correlated with the salivary concentration. The mean saliva/plasma concentration ratio was 0.51 and was independent of the time after ingestion. Salivary nevirapine concentrations were used to estimate the corresponding plasma concentrations for 31 outpatients. Compared with the true plasma concentrations, the estimated concentrations were biased by -4.2%, with a precision of 13.3%. These data show a strong correlation between the salivary and plasma concentrations of nevirapine at a dosage of 200 mg twice daily. This relation has been validated prospectively, and the prediction of plasma concentrations was accurate and precise. Therefore, the authors conclude that saliva can be a useful body fluid for therapeutic drug monitoring of nevirapine.
authors.affiliation: Department of Pharmacy & Pharmacology and Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands. r.p.vanheeswijk@amc.uva.nl
authors.forename: R P
authors.initials: RP
authors.lastname: van Heeswijk
authors.forename: A I
authors.initials: AI
authors.lastname: Veldkamp
authors.forename: J W
authors.initials: JW
authors.lastname: Mulder
authors.forename: P L
authors.initials: PL
authors.lastname: Meenhorst
authors.forename: J H
authors.initials: JH
authors.lastname: Beijnen
authors.forename: J M
authors.initials: JM
authors.lastname: Lange
authors.forename: R M
authors.initials: RM
authors.lastname: Hoetelmans
mesh_terms: D000328:Adult; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D008297:Male; D019829:Nevirapine / Q000493:pharmacokinetics*; D011446:Prospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000493:pharmacokinetics*; D012463:Saliva / Q000378:metabolism*
chemical_list: D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine